1naresh

Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1nareshArray
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)

Table 3: Distribution of contrast enhancement in the AES in relation to histopathologic findings in 42 eyes with retinoblastoma^a
Variable Normal (n = 13) Moderate (n = 15) Strong (n = 14) P Value
Tumor location .88
    Anterior to equator 2 (15) 1 (7) 1 (7) 
    Posterior to equator 8 (62) 8 (53) 8 (57) 
    Combination 3 (23) 6 (40) 5 (36) 
Necrosis .56
    Mean ± SD 24.6 ± 20.0 34.0 ± 21.2 20.7 ± 11.9 
    Range 5–60 5–70 10–50 
Choroidal inflammation .02
    Yes 5 (39) 4 (27) 0 (0) 
    No 8 (62) 11 (73) 14 (100) 
Choroidal invasion .17
    Massive 0 (0) 0 (0) 0 (0) 
    Minimal 4 (31) 4 (27) 1 (7) 
    No 9 (69) 11 (73) 13 (93) 
Scleral invasion 1.00
    Yes 0 (0) 0 (0) 0 (0) 
    No 13 (100) 15 (100) 14 (100) 
AES 1.00
    Yes 0 (0) 1 (7) 0 (0) 
    No 13 (100) 14 (93) 14 (100) 
Optic nerve invasion <.0001
    Postlaminar 0 (0) 1 (7) 2 (14) 
    Prelaminar 2 (15) 5 (33) 10 (71) 
    No 11 (85) 9 (60) 2 (14) 
IA .06
    Stage 3 0 (0) 0 (0) 1 (7) 
    Stage 2 0 (0) 3 (20) 1 (7) 
    Stage 1 1 (8) 4 (27) 4 (29) 
    Stage 0 12 (92) 8 (53) 8 (57) 
Iris vessel count/5 HPF .18
    Mean ± SD 75.8 ± 11.9 83.9 ± 14.6 83.2 ± 14.6 
    Range 56–93 47–102 66–124 
Iris surface-vessel count/5 HPF <.0001^b
    Mean ± SD 3.7 ± 2.8 9.5 ± 6.6 12.8 ± 9.5 
    Range 0–9 1–26 1–32 
a Unless otherwise indicated, data are the number of eyes, and numbers in parentheses are percentages.
b Square-root transformed for statistical analysis because of skewed distribution.